169 related articles for article (PubMed ID: 31734621)
1. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
[TBL] [Abstract][Full Text] [Related]
2. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
3. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
4. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
5. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
6. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
[TBL] [Abstract][Full Text] [Related]
7. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
[TBL] [Abstract][Full Text] [Related]
8. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
9. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U
Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Meinl I; Havla J; Hohlfeld R; Kümpfel T
Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
[TBL] [Abstract][Full Text] [Related]
12. Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
Sacco R; Emming S; Gobbi C; Zecca C; Monticelli S
Mult Scler Relat Disord; 2020 May; 40():101927. PubMed ID: 31931457
[TBL] [Abstract][Full Text] [Related]
13. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
[TBL] [Abstract][Full Text] [Related]
14. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
[TBL] [Abstract][Full Text] [Related]
15. Rebound activity after fingolimod cessation: A case - control study.
Barboza A; Gaitán MI; Alonso R; Ysrraelit MC; Luetic G; Liwacki S; Patrucco L; Halfon MJ; Burgos M; Mainella C; Pierdabuena R; Recchia L; Steinberg J; Tkachuk VA; Zanga G; Carra A; Chertcoff A; Fernandez Liguori N; Lazaro L; Menichini ML; Miguez J; Orzuza G; Palavecino A; Pappolla A; Pigretti S; Pita C; Ruiz E; Silva B; Zentil G
Mult Scler Relat Disord; 2022 Jan; 57():103329. PubMed ID: 35158443
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Nagy S; Kuhle J; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
[TBL] [Abstract][Full Text] [Related]
17. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
Lin W; Chou CH; Yang FC; Tsai CK; Lin YK; Sung YF
Front Immunol; 2023; 14():1115120. PubMed ID: 37122715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
